Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Pharmacokinetic Study of Intravenous Clonidine Versus Midazolam for Sedation in Paediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female~* Aged from birth (≥34 weeks gestational age \[GA\]) to \<17 years, 11 months, 1 week old~* Admitted or expected to be admitted (post-operatively) to PICU~* Existing or expected indication for invasive or non-invasive ventilation (except Continuous Positive Airway Pressure, CPAP)~* Anticipated need for continuous sedation for at least 24 hours~* Informed consent (or deferred consent) obtained from the subject's parent(s) or legal guardian(s)~* Where applicable, assent obtained from the subject to participate in the clinical trial~Exclusion Criteria:~* Body weight less than 1500 g~* Gestational age \[GA\] of \<34 weeks~* Body weight 3 kg or less AND aged 28 days or older~* Body weight less than 10 kg AND aged 2 years old or older~* Body weight greater than 85 kg~* Subjects who will be 18 years old in less than 3 weeks~* Known hypersensitivity to the IMP (clonidine) or comparator (midazolam), or Non Investigational Medicinal Product (morphine, propofol) or any of their formulation ingredients and their rescue medication~* Subjects anticipated to be treated with forbidden concomitant medications during IMP administration~* Subjects less than 24 hours post-resuscitation~* Subjects who have been under sedation for more than 72 hours immediately prior to assessment~* Subjects currently being treated with Extra Corporeal Membrane Oxygenation (ECMO)~* Subjects with treatment-induced whole body hypothermia~* Subjects with severe organ insufficiencies~* Subjects whose condition is assessed by the investigator to have an effect on the level of consciousness which impairs the assessment of sedation (COMFORT-B/NISS)~* Subjects with phaeochromocytoma~* Subjects with severe bradyarrhythmia resulting from either sick-sinus syndrome or atrioventricular (AV) block of 2nd or 3rd degree~* Known arterial hypertension requiring chronic treatment in medical history~* Females who are pregnant, lactating or planning to become pregnant or who return a positive result to a urine pregnancy test (a dipstick and serum pregnancy test will be performed at the screening visit).~* Employee or direct relative of an employee or any member of the study site staff or the Sponsor/ study management staff (applies to subject and/ or subject's parent(s)~* Participation in a clinical intervention study using drugs within the last 3 weeks~* Previous participation in this clinical study at any time~* Parent(s)/ legal guardian(s) decline to give informed consent. If parent(s)/ legal guardian(s) are not present

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- CLONIDINE HYDROCHLORIDE (Type: EXPERIMENTAL): solution for i.v. infusion (maximum 55 μg/kg per day; maximum 7 day treatment)
- MIDAZOLAM (Type: ACTIVE_COMPARATOR): solution for i.v. infusion (maximum 5.5 mg/kg per day; maximum 7 day treatment)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues